Singapore Clinical Trial: A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (NEBULA-1)

Singapore, Sept. 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (NEBULA-1)'. The following are the other relevant details related to the trial:

Therapeutic Area: Hepatology

Trial Centre(s): Changi General Hospital National University Hospital Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Rahul Kumar Dr Mark Dhinesh Muthiah Dr George Goh Boon Bee

Published by HT Digital Content Services with permission from Health Daily Digest....